Association of alopecia areata with hospitalization for mental health disorders in US adults
To the Editor: Patients with alopecia areata (AA) commonly experience psychologic distress and impaired quality of life, 1,2 which may result in mental health (MH) disorders. We sought to determine whether AA is associated with MH disorders.
Data were analyzed from the 2002 to 2012 National Inpatient Sample, which is a representative cross-sectional 20% sample of US hospitalizations (N ¼ 87,053,155 adults and children). AA was identified by International Classification of Diseases, Ninth Revision, Clinical Modification code 704.01. The reference group included all patients without AA. MH comorbidities ( primary or secondary diagnosis) and primary admissions ( primary diagnosis) were determined by Clinical Classification Software codes 650 to 663 and 670. Statistical analyses were performed by using SURVEY procedures, including sample strata, clusters, and discharge trend weights in SAS software (version 9.4, SAS Institute Inc, Cary, NC). Logistic regression models were used to assess associations between AA and MH disorders. Complete case analysis was performed. A 2-sided P value less than .05 was considered statistically significant.
All data were de-identified, and no attempt was made to identify any patients in the database. All parties were compliant with the National Inpatient Sample formal data use agreement. The study was approved by the institutional review board at Northwestern University, and patient consent was waived, as all databases were de-identified. There were 5605 weighted admissions with a diagnosis of AA; more than 99% of AA diagnoses were secondary. In multivariable models, AA was associated with any MH disorder, including 13 of the 15 disorders examined (Fig 1, A) . AA was also associated with primary admission for any MH disorder, including anxiety, mood, attention-deficit/hyperactivity and conduct, and psychotic disorders (Fig 1, B) . The mean length and cost of primary hospitalization for an MH disorder in patients with AA were 6.0 days (range, 5.4-6.6) and $11,907 [range, $10,312-$13,503].
These results expand on previous studies. A questionnaire study of 294 patients with AA found that 8.8% had a major depressive episode and 18.2% had generalized anxiety disorder, compared with only 1.3% to 3.5% and 2.5% of individuals in the general population, respectively.
3 A case-control study of 50 Indian patients with AA found higher rates of clinical depression (38% vs 20%) and anxiety (62% vs 34%) in patients with AA than in controls. 4 Adjustment disorder was commonly found (rate, 14.8%) in a hospital cohort of 32 Spanish patients with AA. 5 A Taiwanese nationwide case-control study found that patients with AA had a higher risk of anxiety and depression. 1 In contrast to our results, AA was associated with a lower risk of schizophrenia and no increased risk of attention-deficit disorder or attention-deficit/hyperactivity disorder. 1 We found higher rates of schizophrenia, and we also found that attention-deficit and conduct disorders had the strongest association with AA. The reasons for these differences are unknown.
Strengths of this study include analysis of a large-scale, nationally representative cohort, with a large number of AA cases. We examined associations of AA with the full-range of MH disorders. The cross-sectional design precluded examining the temporal relationship between AA and MH disorders. Psychosocial impact in AA may contribute to MH disorders, though psychosocial stress of MH disorders may trigger AA. Age of onset, type, and severity of AA were not available. Large-scale prospective studies are needed to address the complex relationship and mechanisms of MH disorders in patients with AA. Conflicts of interest: None disclosed.
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Reprints not available from the authors. Currently, there is a paucity of data regarding the efficacy of FD-specific treatments. This study aimed to provide an evidence-based analysis of current treatment efficacy for FD. Using PRISMA (Preferred Reporting Items for Systemic Reviews and Meta-Analyses) guidelines. PubMed, Medline, Scopus, and the Cochrane library were searched for articles published in English during 1998-2018. Data regarding treatment regimen and efficacy was graded according to the American College of Physicians grading system (Supplemental Fig 1; available at http://www.jaad.org). 2 , Treatment efficacy of FD was discussed in 20 studies that included 282 patients, of which 73.4% were male. The highest level of evidence was grade 3, encompassing 7 studies with 263 patients (Table I) . [3] [4] [5] [6] [7] [8] A multicenter, retrospective study showed that 15 patients treated with a 10-week course of clindamycin and rifampicin achieved the longest disease remission at an average of 7.2 months. The remission period was shorter among those treated with doxycycline or azithromycin for 3-6 months, who subsequently received adjunct topical antibiotics and intralesional corticosteroids. 3 Powell et al demonstrated that a 10-week course of clindamycin and rifampicin achieved remission in 10 of 18 (55.6%) patients for 2-22 months, and 5 additional patients responded after 2-3 more courses. 4 Similarly, Miguel Gomez et al demonstrated a 91% response rate and longer duration of response (5 months) in cases initially refractory to tetracycline treatment. 5 Conversely, a retrospective study by Tietze et al showed 8 of 12 patients treated with a 10-week course of clindamycin and rifampicin relapsed, and 2 had no clinical response. 6 In another retrospective study, 7 of 10 patients treated with combination tetracycline, clobetasol propionate lotion, and intralesional triamcinolone for an average of 7 months were in disease remission for up to 4 years. Continued treatment with oral antibiotics, intralesional triamcinolone, or clobetasol propionate was needed in 11 of 23 patients to maintain remission.
7
Tietze et al 6 demonstrated that isotretinoin treatment for 5-7 months resulted in disease remission for 4-24 months in 9 of 10 patients, 3 of whom required low-dose maintenance. Of note, treatment of FD with isotretinoin was associated with hyperlipidemia (14/39) in another retrospective review. 8 Newer therapeutic options have been described in case reports and case series in recent years, and accordingly, the level of evidence is very low ( grade 4) (Table II) . 1 Red light photodynamic therapy resulted in clinical improvement in 9 of 10 patients, with 6 patients exhibiting disease remission. 1 Additional treatments with lowest evidence were tacrolimus ointment, external beam radiation, isotretinoin, human immunoglobulin, adalimumab, infliximab, and long-pulse neodymium:yttrium aluminum garnet.
Overall, all studies evaluated had small sample sizes, lacked control groups, and randomization. In addition, given the retrospective nature of the included studies, blinding was not possible so observer bias might have occurred. Combination of clindamycin and rifampicin was the most commonly used treatment in reviewed studies. However, based on low quality of evidence, we are unable to discern whether it is the most efficacious treatment. The lack of higher grade evidence highlights the need for stronger studies performed to assess the efficacy of various treatments used for folliculitis decalvans, though the rarity of FD makes this challenging. 
